{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:26:00Z","timestamp":1793229960670,"version":"4.5.0"},"reference-count":57,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is now the most common liver disease worldwide, with a continuously increasing prevalence. The mechanisms involved in its pathophysiology are numerous and may include metabolic, environmental, and genetic factors. Genome-wide association studies have identified key genetic variants, most notably in PNPLA3, TM6SF2, MBOAT7, GCKR, and HSD17B13. This mini review discusses the mechanisms through which these variants contribute to the disease pathogenesis, an area that remains a rapidly evolving field of research. Beyond improving our understanding of MASLD, the identification of these variants may also aid in the development of targeted pharmacological approaches. We first summarize the major genetic variants associated with MASLD and then present findings from studies exploring how these variants may influence the efficacy of emerging pharmacotherapies. Finally, we examine the therapeutic agents in the field of precision medicine that are currently being tested in clinical trials. These therapeutic opportunities are a promising approach that may provide individualized solutions for this chronic liver disorder that affects a wide range of the population.<\/jats:p>","DOI":"10.3390\/ijms27041933","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:50:30Z","timestamp":1771401030000},"page":"1933","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Genetic Predisposition to MASLD: Potential for Therapeutic Management"],"prefix":"10.3390","volume":"27","author":[{"given":"Fani","family":"Karapanagiotidi","sequence":"first","affiliation":[{"name":"4th Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Street, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0053-2440","authenticated-orcid":false,"given":"Chrysoula","family":"Boutari","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Street, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0923-050X","authenticated-orcid":false,"given":"Emmanouil","family":"Sinakos","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Street, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic Steatohepatitis: Mayo Clinic Experiences with a Hitherto Unnamed Disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Juanola, O., Mart\u00ednez-L\u00f3pez, S., Franc\u00e9s, R., and G\u00f3mez-Hurtado, I. (2021). Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18105227"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/1570161115666170621075157","article-title":"Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications","volume":"16","author":"Boutari","year":"2018","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.bbalip.2018.06.018","article-title":"The Role of PNPLA3 in Health and Disease","volume":"1864","author":"Pingitore","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_7","first-page":"55","article-title":"Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine","volume":"13","author":"Zhang","year":"2025","journal-title":"Annu. Rev. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hep.29273","article-title":"The PNPLA3 Variant Associated with Fatty Liver Disease (I148M) Accumulates on Lipid Droplets by Evading Ubiquitylation","volume":"66","author":"BasuRay","year":"2017","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de Novo Lipogenesis Is a Distinct Characteristic of Individuals with Nonalcoholic Fatty Liver Disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin Resistance Drives Hepatic de Novo Lipogenesis in Nonalcoholic Fatty Liver Disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cmet.2023.10.008","article-title":"The PNPLA3 I148M Variant Increases Ketogenesis and Decreases Hepatic de Novo Lipogenesis and Mitochondrial Function in Humans","volume":"35","author":"Luukkonen","year":"2023","journal-title":"Cell Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jhep.2012.07.030","article-title":"Patatin-like Phospholipase Domain-Containing 3 (PNPLA3) I148M (Rs738409) Affects Hepatic VLDL Secretion in Humans and in Vitro","volume":"57","author":"Pirazzi","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","article-title":"Therapeutic Opportunities for the Treatment of NASH with Genetically Validated Targets","volume":"79","author":"Romeo","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.3748\/wjg.v18.i42.6018","article-title":"PNPLA3, the Triacylglycerol Synthesis\/Hydrolysis\/Storage Dilemma, and Nonalcoholic Fatty Liver Disease","volume":"18","author":"Sookoian","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5009\/gnl240407","article-title":"Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"19","author":"Pei","year":"2025","journal-title":"Gut Liver"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.17292","article-title":"Review Article: The Role of HSD17B13 on Global Epidemiology, Natural History, Pathogenesis, and Treatment of NAFLD","volume":"57","author":"Amangurbanova","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"HSD17B13 Is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non-Alcoholic Fatty Liver Disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1073\/pnas.1410741111","article-title":"Comparative Proteomic Study Reveals 17\u03b2-HSD13 as a Pathogenic Protein in Nonalcoholic Fatty Liver Disease","volume":"111","author":"Su","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-Wide Association Study Identifies a TM6SF2 Variant That Confers Susceptibility to Nonalcoholic Fatty Liver Disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.14309\/ajg.0000000000003169","article-title":"TM6SF2-Rs58542926 Genotype Has Opposing Effects on Incidence of Hepatic and Cardiac Events in a Community Cohort","volume":"120","author":"Chen","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 Variant Rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cmet.2016.09.016","article-title":"Hepatocyte TAZ\/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis","volume":"24","author":"Wang","year":"2016","journal-title":"Cell Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/HEP.0000000000000933","article-title":"Low MBOAT7 Expression, a Genetic Risk for MASH, Promotes a Profibrotic Pathway Involving Hepatocyte TAZ Upregulation","volume":"81","author":"Moore","year":"2025","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12328-018-0841-9","article-title":"The Genetic Backgrounds in Nonalcoholic Fatty Liver Disease","volume":"11","author":"Seko","year":"2018","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jhep.2020.04.021","article-title":"MARC1 Variant Rs2642438 Increases Hepatic Phosphatidylcholines and Decreases Severity of Non-Alcoholic Fatty Liver Disease in Humans","volume":"73","author":"Luukkonen","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e0365","DOI":"10.1097\/HC9.0000000000000365","article-title":"MARC1 in MASLD: Modulation of Lipid Accumulation in Human Hepatocytes and Adipocytes","volume":"8","author":"Jones","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","article-title":"Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease","volume":"160","author":"Jamialahmadi","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/path.4803","article-title":"Mitochondrial Genome Architecture in Non-Alcoholic Fatty Liver Disease","volume":"240","author":"Sookoian","year":"2016","journal-title":"J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/joim.13147","article-title":"Liver Mitochondrial DNA Damage and Genetic Variability of Cytochrome b\u2014A Key Component of the Respirasome\u2014Drive the Severity of Fatty Liver Disease","volume":"289","author":"Pirola","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-Wide Association Study of Non-Alcoholic Fatty Liver and Steatohepatitis in a Histologically Characterised Cohort\u2606","volume":"73","author":"Anstee","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jhep.2022.03.031","article-title":"Rare ATG7 Genetic Variants Predispose Patients to Severe Fatty Liver Disease","volume":"77","author":"Baselli","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jhep.2016.06.029","article-title":"Variants in the Autophagy-Related Gene IRGM Confer Susceptibility to Non-Alcoholic Fatty Liver Disease by Modulating Lipophagy","volume":"65","author":"Lin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_33","unstructured":"FDA (2025, October 15). FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease."},{"key":"ref_34","unstructured":"FDA (2025, October 15). FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH\u2019, Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/jgh.12656","article-title":"PNPLA3 Gene Polymorphism and Response to Lifestyle Modification in Patients with Nonalcoholic Fatty Liver Disease","volume":"30","author":"Shen","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41401-022-00860-3","article-title":"Updates on Novel Pharmacotherapeutics for the Treatment of Nonalcoholic Steatohepatitis","volume":"43","author":"Yang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_39","first-page":"16","article-title":"Resmetirom Effects on NASH with Liver Fibrosis in Patients with NASH Genetic Risk Alleles","volume":"20","author":"Chalasani","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2013Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1053\/j.gastro.2023.11.018","article-title":"PNPLA3 Risk Allele Association with ALT Response to Semaglutide Treatment","volume":"166","author":"Urias","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction\u2013Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_43","unstructured":"Sanyal, A., Bugianesi, E., Chalasani, N., Park, Y., Tang, Y., Perfield, J.W., Haupt, A., Hartman, M.L., and Loomba, R. (2024). 5014: \u0399mpact of Pnpla3 Rs738409 Variant on the Response to Tirzepatide versus Placebo for the Treatment of Non-Cirrhotic MASH. AASLD: The Liver Meeting: Late Breaking Abstract Supplement, AASLD."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Deng, M., Wen, Y., Yan, J.X., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., and Lu, Q. (2023). Comparative Effectiveness of Multiple Different Treatment Regimens for Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus: A Systematic Review and Bayesian Network Meta-Analysis of Randomised Controlled Trials. BMC Med., 21.","DOI":"10.1186\/s12916-023-03129-6"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1097\/CM9.0000000000003355","article-title":"Drug Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress and Direction","volume":"137","author":"Zhou","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and Efficacy of Once-Weekly Efruxifermin versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis (HARMONY): 96-Week Results from a Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S719","DOI":"10.1016\/S0168-8278(22)01756-1","article-title":"Efruxifermin Treatment Improved Histopathology and Non-Invasive Markers of Liver Injury and Fibrogenesis in NASH Patients across PNPLA3 Genotypes: A Post Hoc Analysis of the Phase 2a BALANCED Study","volume":"77","author":"Tillman","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","unstructured":"Griffel, L.H., Francque, S.M., Abdelmalek, M.F., Huot-Marchand, P., Dzen, L., Baudin, M., Junien, J.-L., Broqua, P., and Cooreman, M.P. (2023, January 10\u201314). Lanifibranor Improves Liver Histology and Markers of Cardiometabolic Health in Patients with NASH Independent of PNPLA3 Genotype: A Retrospective Analysis of the NATIVE Study. Proceedings of the AASLD The Liver Meeting, Boston, MA, USA."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 Silencing with Antisense Oligonucleotides Ameliorates Nonalcoholic Steatohepatitis and Fibrosis in Pnpla3 I148M Knock-in Mice","volume":"22","author":"Ahnmark","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 Antisense Oligonucleotide, for the Treatment of MASH in 148M Homozygous Participants: Two Randomized Phase I Trials","volume":"83","author":"Armisen","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 Trials of PNPLA3 SiRNA in I148M Homozygous Patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.pharmr.2024.100018","article-title":"Pharmacological Treatment for Metabolic Dysfunction\u2013Associated Steatotic Liver Disease and Related Disorders: Current and Emerging Therapeutic Options","volume":"77","author":"Zhang","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A Phase I\/II Study of ARO-HSD, an RNA Interference Therapeutic, for the Treatment of Non-Alcoholic Steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jhep.2025.05.031","article-title":"Phase 1 Randomized Double-Blind Study of an RNA Interference Therapeutic Targeting HSD17B13 for Metabolic Dysfunction\u2013Associated Steatohepatitis","volume":"83","author":"Sanyal","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","article-title":"Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease","volume":"150","author":"Anstee","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1194\/jlr.P055640","article-title":"Polyunsaturated Fatty Acid Metabolites as Novel Lipidomic Biomarkers for Noninvasive Diagnosis of Nonalcoholic Steatohepatitis","volume":"56","author":"Loomba","year":"2015","journal-title":"J. Lipid Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1933\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:51:48Z","timestamp":1771401108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041933"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041933","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}